MX2023002418A - Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas. - Google Patents
Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas.Info
- Publication number
- MX2023002418A MX2023002418A MX2023002418A MX2023002418A MX2023002418A MX 2023002418 A MX2023002418 A MX 2023002418A MX 2023002418 A MX2023002418 A MX 2023002418A MX 2023002418 A MX2023002418 A MX 2023002418A MX 2023002418 A MX2023002418 A MX 2023002418A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- atherosclerosis
- baseline
- increase
- level
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 5
- 208000020832 chronic kidney disease Diseases 0.000 abstract 4
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- 208000028208 end stage renal disease Diseases 0.000 abstract 2
- 201000000523 end stage renal failure Diseases 0.000 abstract 2
- 208000030613 peripheral artery disease Diseases 0.000 abstract 2
- 101150092476 ABCA1 gene Proteins 0.000 abstract 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 abstract 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 abstract 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 abstract 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 abstract 1
- 206010038378 Renal artery stenosis Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000000642 iatrogenic effect Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan en el presente documento métodos para tratar aterosclerosis y/o una enfermedad cardiovascular aterosclerótica (por ejemplo, enfermedad de la arteria coronaria (CAD), enfermedad arterial periférica (PAD), enfermedad vascular periférica (PVD), accidente cerebrovascular, enfermedad renal crónica (CKD) causada por aterosclerosis, enfermedad renal en etapa terminal (ESKD) causada por aterosclerosis, falla renal aguda causada por aterosclerosis, enfermedad renovascular aterosclerótica (ARVD), estenosis arterial renal, aneurisma aórtico, hipertensión atrial periférica idiopática, disfunción eréctil, claudicación intermitente, enfermedad arterial posquirúrgica o iatrogénica) mediante la administración de una cantidad terapéuticamente efectiva de 2-hidroxipropil-beta-ciclode xtrina al sujeto. En algunos casos, la cantidad terapéuticamente efectiva es una cantidad suficiente para aumentar el nivel en circulación y/o sistémico de uno o más esteroles u oxisteroles en el sujeto en comparación con un valor de referencia, una cantidad efectiva para aumentar un nivel de ABCA1 y/o ABCG1 en el sujeto en comparación con el valor de referencia, una cantidad efectiva para aumentar el nivel de capacidad de disolución de cristales de colesterol en plasma en el sujeto en comparación con el valor de referencia o cualquier combinación de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071257P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/048084 WO2022047249A1 (en) | 2020-08-27 | 2021-08-27 | Methods for the treatment of cardiovascular disease with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002418A true MX2023002418A (es) | 2023-07-11 |
Family
ID=80353287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002418A MX2023002418A (es) | 2020-08-27 | 2021-08-27 | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240000826A1 (es) |
| EP (1) | EP4203974A1 (es) |
| JP (1) | JP2023543131A (es) |
| KR (1) | KR20230104119A (es) |
| CN (1) | CN116322644A (es) |
| AU (1) | AU2021331487A1 (es) |
| CA (1) | CA3189915A1 (es) |
| CO (1) | CO2023003656A2 (es) |
| CR (1) | CR20230135A (es) |
| IL (1) | IL300805A (es) |
| MX (1) | MX2023002418A (es) |
| PE (1) | PE20231169A1 (es) |
| WO (1) | WO2022047249A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| CN104244956B (zh) * | 2012-04-13 | 2020-04-17 | L&F研究有限公司 | 使用环糊精的方法 |
-
2021
- 2021-08-27 EP EP21862882.4A patent/EP4203974A1/en active Pending
- 2021-08-27 KR KR1020237010388A patent/KR20230104119A/ko unknown
- 2021-08-27 AU AU2021331487A patent/AU2021331487A1/en active Pending
- 2021-08-27 WO PCT/US2021/048084 patent/WO2022047249A1/en active Application Filing
- 2021-08-27 MX MX2023002418A patent/MX2023002418A/es unknown
- 2021-08-27 CN CN202180053234.0A patent/CN116322644A/zh active Pending
- 2021-08-27 US US18/023,325 patent/US20240000826A1/en active Pending
- 2021-08-27 PE PE2023000716A patent/PE20231169A1/es unknown
- 2021-08-27 IL IL300805A patent/IL300805A/en unknown
- 2021-08-27 CR CR20230135A patent/CR20230135A/es unknown
- 2021-08-27 JP JP2023513670A patent/JP2023543131A/ja active Pending
- 2021-08-27 CA CA3189915A patent/CA3189915A1/en active Pending
-
2022
- 2022-11-11 US US17/985,762 patent/US20230091966A1/en not_active Abandoned
-
2023
- 2023-03-23 CO CONC2023/0003656A patent/CO2023003656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230091966A1 (en) | 2023-03-23 |
| IL300805A (en) | 2023-04-01 |
| JP2023543131A (ja) | 2023-10-13 |
| CN116322644A (zh) | 2023-06-23 |
| CA3189915A1 (en) | 2022-03-03 |
| CR20230135A (es) | 2023-07-19 |
| CO2023003656A2 (es) | 2023-08-09 |
| US20240000826A1 (en) | 2024-01-04 |
| AU2021331487A1 (en) | 2023-03-16 |
| EP4203974A1 (en) | 2023-07-05 |
| WO2022047249A1 (en) | 2022-03-03 |
| KR20230104119A (ko) | 2023-07-07 |
| PE20231169A1 (es) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dijkstra et al. | Editor's Choice–Spinal cord ischaemia in endovascular thoracic and thoraco-abdominal aortic repair: review of preventive strategies | |
| Kearon et al. | Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism | |
| Dhaun et al. | Blood pressure–independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease | |
| Matsumura et al. | Left subclavian artery revascularization: Society for Vascular Surgery® practice guidelines | |
| MX2023002418A (es) | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas. | |
| Reza Khoshdel et al. | Circulatory syndrome: an evolution of the metabolic syndrome concept! | |
| De Feyter | Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem | |
| Kannan et al. | Coronary revascularization in chronic and end-stage renal disease: a systematic review and meta-analysis | |
| Thom et al. | Anticoagulation in children undergoing cardiac surgery | |
| Isik et al. | A comparison of direct versus conventional stenting in patients undergoing primary angioplasty for ST-elevation myocardial infarction | |
| Biondi | Is there any reason to treat subclinical hypo and hyperthyroidism? | |
| MacRae | Vascular access and cardiac disease: is there a relationship? | |
| AR073233A1 (es) | Uso de inhibidores de epoxido hidrolasa soluble, como por ejemplo 1-adamantil-3-(1-acetilpiperidin-4-il) urea, en el tratamiento de enfermedades vasculares inflamatorias, metodo para identificar una enfermedad tratable y stent | |
| Zhao et al. | Comparative analysis of left atrial appendage closure efficacy and outcomes by CHA2DS2-VASc score group in patients with non-valvular atrial fibrillation | |
| Yevzlin et al. | Hand ischemia in a patient with an arteriovenous fistula | |
| Ledingham | Heyde's syndrome: exploring the link between aortic stenosis and an acquired bleeding disorder | |
| Young et al. | Venous ulcer: late complication of a traumatic arteriovenous fistula | |
| Abbott et al. | Treatment of a Left Internal Mammary Artery to Pulmonary Artery Fistula with Polytetrafluoroethylene Covered Stents: A Case Report and Review of the Literature | |
| Khan et al. | Successful treatment of giant left subclavian artery pseudoaneurysm abutting the arch of the aorta and descending aorta | |
| Pande et al. | Complete resolution of extensive thrombosis of atheromatous non-aneurysmal descending aorta and pulmonary embolism with warfarin therapy | |
| Panfilov et al. | Frozen Elephant Trunk Technique to Treat Extensive Thoracic Aortic Mural Thrombus | |
| ASSESSMENT et al. | Career Development Abstracts | |
| Katikaneni et al. | Antiphospholipid Syndrome (APS)-An Update on Clinical Features and Treatment Options | |
| Moore et al. | Journal of Critical Limb Ischemia | |
| Salvi et al. | Arterial Stiffness in Chronic Kidney Disease |